[go: up one dir, main page]

HK1064683A1 - Receptor of the edb fibronectin domains (II) - Google Patents

Receptor of the edb fibronectin domains (II)

Info

Publication number
HK1064683A1
HK1064683A1 HK04107490A HK04107490A HK1064683A1 HK 1064683 A1 HK1064683 A1 HK 1064683A1 HK 04107490 A HK04107490 A HK 04107490A HK 04107490 A HK04107490 A HK 04107490A HK 1064683 A1 HK1064683 A1 HK 1064683A1
Authority
HK
Hong Kong
Prior art keywords
receptor
sub
fibronectin domains
edb fibronectin
edb
Prior art date
Application number
HK04107490A
Other languages
English (en)
Inventor
Alexander REDLITZ
Marcus Koppitz
Ursula Egner
Andreas Menrad
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10045803A external-priority patent/DE10045803A1/de
Priority claimed from DE2001123133 external-priority patent/DE10123133A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of HK1064683A1 publication Critical patent/HK1064683A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK04107490A 2000-09-07 2004-09-28 Receptor of the edb fibronectin domains (II) HK1064683A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10045803A DE10045803A1 (de) 2000-09-07 2000-09-07 Rezeptor der EDb Fibronektin-Domäne
DE2001123133 DE10123133A1 (de) 2001-05-02 2001-05-02 Rezeptor der ED¶b¶-Fibronektin-Domäne (II)
PCT/EP2001/010016 WO2002020563A2 (de) 2000-09-07 2001-08-30 REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II)

Publications (1)

Publication Number Publication Date
HK1064683A1 true HK1064683A1 (en) 2005-02-04

Family

ID=26007070

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107490A HK1064683A1 (en) 2000-09-07 2004-09-28 Receptor of the edb fibronectin domains (II)

Country Status (24)

Country Link
US (3) US20020197700A1 (zh)
EP (1) EP1381629B1 (zh)
JP (1) JP2004529848A (zh)
KR (1) KR20030045056A (zh)
CN (1) CN1246333C (zh)
AT (1) ATE407951T1 (zh)
AU (1) AU1218202A (zh)
BG (1) BG107614A (zh)
BR (1) BR0113737A (zh)
CA (1) CA2421783A1 (zh)
DE (1) DE50114321D1 (zh)
EE (1) EE200300092A (zh)
ES (1) ES2312478T3 (zh)
HK (1) HK1064683A1 (zh)
HR (1) HRP20030263A2 (zh)
HU (1) HUP0300935A3 (zh)
IL (1) IL154778A0 (zh)
NO (1) NO20031033L (zh)
NZ (1) NZ524342A (zh)
PL (1) PL364358A1 (zh)
RU (1) RU2280254C2 (zh)
SK (1) SK2882003A3 (zh)
WO (1) WO2002020563A2 (zh)
YU (1) YU17503A (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062800A1 (en) 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ATE463512T1 (de) 2005-11-09 2010-04-15 Morphosys Ag Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
BRPI0809989B8 (pt) 2007-04-02 2021-05-25 Philogen Spa usos de um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a isoforma extradomínio-a (ed-a) de fibronectina e/ou ao ed-a de fibronectina
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
BRPI0818272B8 (pt) * 2007-10-30 2021-05-25 Philogen Spa uso de um membro de ligação que se liga à isoforma extra domínio-a (ed-a) da fibronectina para a preparação de um medicamento para tratamento de artrite reumatóide
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
EP2461832B1 (en) 2009-08-05 2017-06-28 Philogen S.p.A. Targeting of bone marrow neovasculature
PL2903629T3 (pl) 2012-10-03 2019-12-31 Philogen S.P.A. Koniugat przeciwciała do zastosowania w leczeniu nieswoistego zapalenia jelita
EP3689903A4 (en) * 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. FIBRONECTIN B DOMAIN BINDING PROTEIN

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341223A (en) * 1981-02-04 1982-07-27 Lutz Lauralee A Fluoresceable composition and method of determining fluid flow
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US4894326A (en) * 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5243029A (en) * 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US5177015A (en) * 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
EP0486622B1 (en) * 1989-08-09 1998-11-04 Rhomed, Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5120830A (en) * 1990-10-25 1992-06-09 Washington University Inhibitory peptides against α-2, β-1 mediated mg++ dependent adhesion of platelets to collagen
US5629291A (en) * 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
EP1997894B1 (en) * 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5561114A (en) * 1992-09-25 1996-10-01 Otsuka Pharmaceutical Factory Inc. Adsorbent for cellular fibronectin, a method for fractional purification of fibronectin and a method of hemocatharisis
JP3339724B2 (ja) * 1992-09-29 2002-10-28 株式会社リコー インクジェット記録方法及びその装置
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) * 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5648485A (en) * 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
DE4445065A1 (de) * 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US5808146A (en) * 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US5842156A (en) * 1996-11-12 1998-11-24 The United States Of America As Represented By The Secretary Of The Air Force Multirate multiresolution target tracking
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US6394952B1 (en) * 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) * 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US5997842A (en) * 1998-04-13 1999-12-07 Light Sciences Limited Partnership Radionuclide excited phosphorescent material for administering PDT
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US6630570B1 (en) * 1999-04-09 2003-10-07 Insitut für Diagnostikforschung GmbH Short-chain peptide-dye conjugates as contrast media for optical diagnosis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
EP1267935A2 (en) * 2000-01-12 2003-01-02 Light Sciences Corporation Novel treatment for eye disease
ATE526039T1 (de) * 2000-02-24 2011-10-15 Philogen Spa Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
US6342326B1 (en) * 2000-05-10 2002-01-29 Beckman Coulter, Inc. Synthesis and use of acyl fluorides of cyanine dyes
WO2002069907A2 (en) * 2001-03-07 2002-09-12 Mannkind Corporation Anti-neovasculature preparations for cancer
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
AR040956A1 (es) * 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico

Also Published As

Publication number Publication date
RU2003109431A (ru) 2005-01-20
US20050221434A1 (en) 2005-10-06
RU2280254C2 (ru) 2006-07-20
NO20031033D0 (no) 2003-03-06
CN1487953A (zh) 2004-04-07
EP1381629A2 (de) 2004-01-21
JP2004529848A (ja) 2004-09-30
HUP0300935A3 (en) 2005-09-28
EP1381629B1 (de) 2008-09-10
CA2421783A1 (en) 2002-03-14
KR20030045056A (ko) 2003-06-09
NZ524342A (en) 2005-09-30
US20020197700A1 (en) 2002-12-26
EE200300092A (et) 2005-06-15
CN1246333C (zh) 2006-03-22
SK2882003A3 (en) 2003-08-05
BR0113737A (pt) 2004-02-25
YU17503A (sh) 2006-05-25
HUP0300935A2 (hu) 2003-12-29
IL154778A0 (en) 2003-10-31
ATE407951T1 (de) 2008-09-15
US20050089941A1 (en) 2005-04-28
AU1218202A (en) 2002-03-22
HRP20030263A2 (en) 2005-10-31
WO2002020563A2 (de) 2002-03-14
DE50114321D1 (de) 2008-10-23
ES2312478T3 (es) 2009-03-01
BG107614A (bg) 2003-12-31
PL364358A1 (en) 2004-12-13
NO20031033L (no) 2003-05-07
WO2002020563A3 (de) 2003-10-09

Similar Documents

Publication Publication Date Title
PL360373A1 (en) Non-imidazole aryloxypiperidines as h3 receptor ligands
ZA200603731B (en) Plasmid system for multiple expression
WO2003062375A3 (en) Stabilizing polypeptides which have been exposed to urea
HK1066810A1 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
GB0031527D0 (en) New use
HK1064683A1 (en) Receptor of the edb fibronectin domains (II)
NO20022663D0 (no) Substituerte ftalocyaniner og deres forlöpere
MXPA01008347A (es) Compuestos quimicos.
ZA200307365B (en) Antibodies specific for CD44V6.
DE69923587D1 (de) Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
MY133390A (en) Azabicyclic 5ht1 receptor ligands
ATE508633T1 (de) Eprosartan-zusammensetzungen
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
PT1282617E (pt) Derivados de hidantoína com afinidade para os receptores da somatostatina
GB0103045D0 (en) Organic Compounds
HK1077827A1 (en) Diazabicyclononane and-decane derivatives their use as opioid receptor ligands
YU30499A (sh) Endotelin intermedijari dobijeni pomoću asimetrične konjugovane adicione reakcije koristeći hiralni aditiv
ATE234837T1 (de) 3-bicycloindole als liganden des 5-ht 1d rezeptors
MX258626B (es) Proceso para la produccion de materiales de gasolina.
WO2002064621A3 (en) Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
AU2002359332A1 (en) Noe-nmr based methods for the identifycation of compounds which can bind to membrane receptors
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
PT1066250E (pt) Sintese convergente de alfa-aril-beta-cetonitrilos
TW200420553A (en) Process for the synthesis of 3, 3a, 6, 6a-tetrahydro-2H-cyclopentan[b]furan-2-one

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090830